[Disclosure] Samsung Biologics(207940) Amends Stock Futures & Options Final Trading Day to Oct 29 Following Revision of Restructuring Schedule

Fact Source: Financial Supervisory Service DART / 2025-08-22

Disclosure Type: Amending Report / Investment Caution Notice for Stock Futures & Options

💡 3-Second Summary

In accordance with the amended corporate split disclosure, the final trading day for stock futures and options based on Samsung Biologics has been modified to October 29, 2025, along with revised baseline dates for the suspension of new contract listings.

📊 1. [Key Disclosure Content & Summary of Financial Figures]

• Company Name: Samsung Biologics Co., Ltd. (207940)
• Amended Document: ‘Investment Caution Notice for Stock Futures & Options (Notice on Scheduled Market Measures for Stock Futures & Options due to Corporate Split)’ originally filed on May 29, 2025.
• Reason for Amendment: Reflecting the amended disclosure on the corporate split decision of Samsung Biologics Co., Ltd. dated August 22, 2025.
• Summary of Core Revisions:
  • Affected Contracts (7-1):
    • [Pre-revision] Oct ’25*, Nov ’25*, Dec ’25, Mar ’26, Jun ’26*, Sep ’26*
    • [Post-revision] Nov ’25, Dec ’25, Jan ’26*, Mar ’26, Jun ’26, Sep ’26* (* denotes scheduled to be listed later)
  • Revised Final Trading Day (7-2):
    • [Pre-revision] September 26, 2025 (The trading day immediately preceding the start date of trading suspension for the underlying stock)
    • [Post-revision] October 29, 2025 (The trading day immediately preceding the start date of trading suspension for the underlying stock)
  • Suspension of New Contract Listings (8):
    • [Pre-revision] Halted after the General Meeting of Shareholders’ approval date (September 16, 2025)
    • [Post-revision] Halted after the General Meeting of Shareholders’ approval date (October 17, 2025)
• Other Material Information: The above measures may be subject to further change depending on the timeline and outcome of the company’s General Meeting of Shareholders.

📈 2. [Expert Insight: What This Disclosure Means for Investors]

This announcement operates as an amendment report notifying market participants of revised technical schedules within the derivatives market due to the adjusted corporate split timeline, rather than denoting changes in the company’s financial figures or underlying fundamentals (Fundamental). Based on the revised filing, the final trading day for relevant stock futures and options has been shifted to October 29, and the baseline shareholder meeting date for freezing new contract listings has been adjusted to October 17.

Accordingly, investors holding or trading these specific derivative contracts should carefully verify the amended schedule provided in this filing. As specific schedules or sub-processes regarding the underlying cash stock are not directly detailed within this disclosure, investors should monitor upcoming official corporate filings or subsequent notices to track the comprehensive timeline.

📝 Editor’s Comment (by K-STOCK Editor)

Market measures for stock futures and options have been amended in alignment with the adjustment of Samsung Biologics’ corporate split timeline. The core fact is that the final trading day for certain stock futures and options has been changed to October 29, and the shareholder meeting date that triggers the freeze on listing new contract months has been deferred to October 17. Derivatives market participants must verify these updated timelines for their positions, and it is advisable to verify further schedules regarding the underlying cash asset through upcoming official disclosures.

📢 Disclaimer & Source Information

Source: This content has been structured and newly generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.